Why this analyst just rated shares of HEXO a “buy”

: HEXO | HEXO Corp. News, Ratings, and Charts

HEXO – Yesterday MKM Partners analyst Bill Kirk initiated coverage of Hexo Corp. (HEXO) with a “buy” rating.

Yesterday MKM Partners analyst Bill Kirk initiated coverage of Hexo Corp. (HEXO) with a “buy” rating, taking the most optimistic stance on this stock out of the 8 cannabis stocks that he began covering.

Kirk gives HEXO stock a C$12.00 price target and predicts a 130% gain in the next 12 months. While other analysts may not be giving HEXO the benefit of the doubt, Kirk seems confident that the company will hit its 2020 revenue target of C$400 million.

“We believe HEXO’s approach to be the working component of expert partners’ products has the best chance of creating a defensible brand (‘Powered by HEXO’),” Kirk wrote in a note to investors.

Part of the reason Kirk is bullish on HEXO is because compared to its cannabis peers, Hexo Corp. has a strong balance sheet of cash reserves ($129 million) and relatively little debt ($23 million) to offset it.

 

It’s all about the edibles

But perhaps more importantly, Kirk is found of HEXO’s business model and how the company is positioning itself in THC edibles market. Part of that positioning is their key partnership with Molson Coors, with which HEXO operates a joint venture.

While Molson Coors provides a vast distribution network for their products, HEXO offers the key ingredient for cannabis-infused beverages, cosmetics and food. HEXO has even trademarked its slogan “Powered by HEXO” to advertise the importance of their ingredients in their partners’ products.

The company’s strong branding positioning is important, notes Kirk, because it sets HEXO up so that the company’s product won’t become commoditized like so many other cannabis product categories have become.

In other words, HEXO isn’t succumbing to the race to the cheapest gram, which could quickly become a race to the bottom, pending oversupply concerns. It’s good that the company knows its place, because HEXO has less growing capacity than rivals “Canopy, Aurora, and Tilray,” said Kirk.

By focusing on the edible game, HEXO will face off against only one other major rival (Canopy Growth Corp), should Recreation 2.0 go through as planned this mid-December when Canada legalizes edibles.

With all of that being said, HEXO stock is still down more than half from its late-April highs from earlier this year (along with the rest of the cannabis sector). In the company’s Q3 earnings report, 84% of the company’s revenue came from flower.

While the company has made it clear that it’s moving away from flower to focus on the edibles market, it now puts the company in a situation of having most of its eggs in one basket – a gift basket that should hopefully be ready to open come mid-December.

Until then, investors will be looking for a show of strength in the company’s upcoming earnings report. Stay tuned for HEXO’s upcoming earnings release scheduled for September 26, 2019.

 

 


HEXO shares . Year-to-date, HEXO has gained 27.11%, versus a 20.46% rise in the benchmark S&P 500 index during the same period.


About the Author: Eric Bowler


Eric is an accomplished journalist providing in-depth insights for more than two decades, with a special focus on the cannabis industry. Learn more about Eric’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
HEXOGet RatingGet RatingGet Rating
CGCGet RatingGet RatingGet Rating
ACBGet RatingGet RatingGet Rating
CRONGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating
TLRYGet RatingGet RatingGet Rating
CTSTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Should Investors BEWARE this Market?

The S&P 500 (SPY) has been on a tear since November 1st when the Fed started to make their dovish tilt opening the door to future rate cuts. Unfortunately they keep not happening and start date keeps getting pushed further and further out. That has many wondering if stocks are getting ahead of themselves setting things up for a fall. Thus a good time to tune into what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Is the Bull Market Growing Tired?

On the one hand it is fun to celebrate the new highs for the S&P 500 (SPY) that came in this Tuesday. On the other hand...it doesn’t make a lot of sense calling into question the next moves for the stock market. Read on below to appreciate investment veteran, Steve Reitmeister’s, market outlook and top picks to outperform.

Read More Stories

More HEXO Corp. (HEXO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All HEXO News